1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model

BACKGROUND: ASN100 is a combination of two co-administered fully human monoclonal antibodies (mAbs), ASN-1 and ASN-2, that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis. ASN100 is in development for prevention of S. aureus pneumonia in mechanically ventilated pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubino, Christopher M, Stulik, Lukas, Rouha, Harald, Visram, Zehra, Badarau, Adriana, Wart, Scott A Van, Ambrose, Paul G, Goodwin, Matthew M, Nagy, Eszter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252729/
http://dx.doi.org/10.1093/ofid/ofy210.1219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252729/
http://dx.doi.org/10.1093/ofid/ofy210.1219

Ejemplares similares